EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Tristar Wellness (TWSI) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Tristar Wellness $0.00, price $0.00, upside -25.0%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US89678H1068

TW Tristar Wellness logo Thin data Sep 27, 2026

Tristar Wellness

TWSI · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $0.0003 · Overvalued (−25.0%)
!Quality 25/100
!Mixed Growth (revenue 5y +43.2 %/yr)
!Loss-making · -177.0% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Tristar Wellness for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.2890 $0.0001 Fair Value $0.0003 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0001 – $0.2890 · the $0.0004 price screens above the $0.0003 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Tristar Wellness in your weekly email

Every Wednesday you see whether Tristar Wellness is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tristar Wellness Solutions Inc. engages in the development, marketing, and sale of wound care products.

Show more

Tristar Wellness Solutions Inc. engages in the development, marketing, and sale of wound care products. The company offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with Invertible Diaphragm, which is a medical applicator for delivering medicants and internal devices within the body without producing injury or damage. It also develops over-the-counter itch suppression products; and develops, manufactures, and markets wound care and infection control medical devices. The company was formerly known as BioPack Environmental Solutions, Inc. and changed its name to Tristar Wellness Solutions Inc. in January 2013. Tristar Wellness Solutions Inc. was incorporated in 2000 and is based in Portland, Oregon. On January 15, 2016, TriStar Wellness Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Oregon.

Stock analysis

Tristar Wellness (TWSI) currently trades at $0.0004, while our model-based Fair Value estimate is $0.0003, 25.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Tristar Wellness reported revenue of $5.5M in FY2014 versus $921K in FY2010, a compound +56.7%/yr. Reported net income was −$18.4K in FY2024.

Key figures

Market cap $132K · P/S ratio 0.03 · EPS (TTM) $−0.0200 · Net margin −177% · Return on assets (EBIT) −2,587% · Operating margin −65.8% · Revenue (TTM) $4.0M · Revenue growth (YoY) −49.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −25%, TWSI screens richer than that median.

Fair Value models

Bear $0.0003 Fair Value $0.0003 Bull $0.0003
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings $0.0002 $0.0004 $0.0009 68
All 1 models by family
DCF Models
Owner Earnings $0.0002 $0.0004 $0.0009 68

Open the full fair value analysis →

Notify me when TWSI reaches fair value

Put TWSI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 29 · Market factors (momentum, volatility) 2

Profitability 36
Margins and returns on capital today
Quality Growth 59
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 7
Balance sheet, leverage, solvency risk
Investment 48
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 4
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+47.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.2%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+100.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−137.1% (2008) → −92.3% (2014)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

TWSI screens overvalued: fair value 25% below the price. Compare with Merck KGaA →

Compare Tristar Wellness with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −25.0% · Below median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −63.8% · Bottom 25%
Net margin (TTM) −177.0% · Bottom 25%
Operating margin (TTM) −65.8% · Bottom 25%
Growth and dividend
Revenue growth −49.9% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.03× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tristar Wellness · Fair Value
$0.0003 −25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Tristar Wellness Fair Value". https://www.fairvalue-calculator.com/stock/TWSI

Frequently asked questions

Is Tristar Wellness (TWSI) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0003 versus the last price from Sep 25, 2026 of $0.0004, about −25% upside (overvalued).
What is the fair value of TWSI?
Our model-based fair value for Tristar Wellness is $0.0003 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0004.
What is the quality score of TWSI?
Tristar Wellness has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tristar Wellness (TWSI)?
Our model-based price target is the fair value of $0.0003 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Tristar Wellness stock forecast for 2026?
Our models put fair value at $0.0003, about −25% upside versus the last price from Sep 25, 2026 of $0.0004 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Tristar Wellness (TWSI)?
Tristar Wellness reported trailing-twelve-month revenue of about $4.0M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Tristar Wellness (TWSI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tristar Wellness it is $0.0003 per share (as of Sep 27, 2026), against a price of $0.0004. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Tristar Wellness stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TWSI trades above its calculated fair value: price $0.0004, fair value $0.0003, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TWSI?
No. The price is what the market pays today ($0.0004); the fair value is what the company's own numbers justify ($0.0003). For Tristar Wellness the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tristar Wellness worth?
The market values Tristar Wellness at about $132K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0004; our models calculate a fair value of $0.0003 per share.
How solid is the balance sheet of Tristar Wellness (TWSI)?
Balance-sheet figures for Tristar Wellness (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is TWSI from its 52-week high?
Tristar Wellness trades at $0.0004, about 100% below its 52-week high of $0.2890 and at the low of $0.0004 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0003 is for.
Which stocks are comparable to Tristar Wellness?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tristar Wellness stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0004, calculated fair value $0.0003 (−25%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TWSI calculated?
We run Tristar Wellness through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0003, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tristar Wellness itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tristar Wellness (TWSI)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0004. Our model-based fair value is $0.0003, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tristar Wellness right now?
The price sits above even our optimistic bull case ($0.0003). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tristar Wellness

How large is the market capitalisation of Tristar Wellness (TWSI)?
The market capitalisation of Tristar Wellness is $132K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tristar Wellness (TWSI)?
The price-to-sales ratio of Tristar Wellness is 0.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tristar Wellness (TWSI)?
Earnings per share at Tristar Wellness are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tristar Wellness (TWSI)?
The net margin of Tristar Wellness is −177% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Tristar Wellness (TWSI)?
On an EBIT basis the return on assets of Tristar Wellness is −2,587% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tristar Wellness (TWSI)?
The operating margin of Tristar Wellness is −65.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tristar Wellness (TWSI)?
Revenue at Tristar Wellness is growing −49.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tristar Wellness (TWSI) generate?
The free cash flow of Tristar Wellness is −$4.6M (fiscal year 2014). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tristar Wellness (TWSI) carry?
The net debt of Tristar Wellness is $9.3M (fiscal year 2014). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tristar Wellness in the live analysis

One click puts Tristar Wellness on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.